Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 9/20 | 0.68 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114281 | 0.91 | CSNK1E (0.81) | CSNK1ERIPK3PIM1LATS1EIF2AK4 | |
| SCHEMBL1746568 | 0.90 | CSNK1E (0.77) | CSNK1ERIPK3LATS1 | |
| SCHEMBL3123887 | 0.90 | CSNK1E (0.80) | CSNK1ERIPK3PIM1LATS1EIF2AK4 | |
| SCHEMBL3105787 | 0.89 | CSNK1E (0.81) | CSNK1ERIPK3LATS1 | |
| SCHEMBL3114184 | 0.87 | CSNK1E (0.57) | CSNK1ERIPK3 | |
| SCHEMBL477008 | 0.87 | CSNK1E (0.63) | CSNK1ERIPK3PIM1LATS1EIF2AK4 | |
| SCHEMBL3107009 | 0.82 | CSNK1E (0.79) | CSNK1ERIPK3PIM1LATS1EIF2AK4 | |
| SCHEMBL477079 | 0.82 | CSNK1E (0.57) | CSNK1ERIPK3PIM1LATS1EIF2AK4 | |
| SCHEMBL3116817 | 0.81 | CSNK1E (1.00) | CSNK1ERIPK3LATS1 | |
| SCHEMBL1744576 | 0.80 | CSNK1E (0.92) | CSNK1ERIPK3LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170889-B1 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | claimed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | claimed |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-10 | — | — | US | claimed |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | US | claimed |
| EP-2170889-B1 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | disclosed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | disclosed |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-10 | — | — | US | disclosed |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | CSNK1E 555/4885RIPK3 3076/4885PIM1 3395/4885 |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | CSNK1E 555/4885RIPK3 3076/4885PIM1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.